The impact of minor histocompatibility antigens in allogeneic stem cell transplantation - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 56

[89] Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic
vaccination of cancer patients: the need to apply therapeutic vaccination strategies in
the preventive setting. Immunol Rev 2008;222:316-27.
[90] Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer im-
munoediting: from tumor tolerance to eradication. Immunol Rev 2011;241:104-18.
[91] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles
in cancer suppression and promotion. Science 2011;331:1565-70.
[92] Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E. Targeting a single
mismatched minor histocompatibility antigen with tumor-restricted expression eradi-
cates human solid tumors. Blood 2008;112:1844-52.
[93] Spaapen RM, Groen RW, van den OK, Guichelaar T, van Elk M, Aarts-Riemens T, et al.
Eradication of medullary multiple myeloma by CD4 + cytotoxic human T lymphocytes
directed at a single minor histocompatibility antigen. Clin Cancer Res 2010;16:5481-8.
[94] Hambach L, Nijmeijer BA, Aghai Z, Schie ML, Wauben MH, Falkenburg JH, et al.
Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen
HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leuke-
mia 2006;20:371-4.
[95] Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of im-
munotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes
specific for hematopoietic system-restricted minor histocompatibility antigens. Blood
1999;93:2336-41.
[96] Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R, et al. Cytotoxic
minor histocompatibility antigen HA-1-specific CD8 + effector memory T cells: artificial
APCs pave the way for clinical application by potent primary in vitro induction. Blood
2005;106:144-9.
[97] Oosten LE, Blokland E, van Halteren AG, Curtsinger J, Mescher MF, Falkenburg JH,
et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompat-
ibility antigen-specific cytotoxic T lymphocytes. Blood 2004;104:224-6.
[98] Mutis T. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor
histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-
host disease after allogeneic stem cell transplantation. Int J Hematol 2003;78:208-12.
[99] Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular im-
munotherapy in leukaemia. Best Pract Res Clin Haematol 2004;17:415-25.
[100] Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, et al. IL-7 recep-
tor expression identifies suicide gene-modified allospecific CD8 + T cells capable of
self-renewal and differentiation into antileukemia effectors. Blood 2011;117:6469-78.
[101] Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy
E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene
transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes
expressing a conserved alpha joining region. Blood 2003;102:3530-40.
[102] Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg
JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell
receptor gene transfer. J Exp Med 2004;199:885-94.
[103] Spaapen RM, van den OK, Ivanov R, Bloem AC, Lokhorst HM, Mutis T. Rebuilding hu-
man leukocyte antigen class II-restricted minor histocompatibility antigen specificity
in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for
adoptive immunotherapy. Clin Cancer Res 2007;13:4009-15.
[104] van Loenen MM. de BR, Hagedoorn RS, van Egmond EH, Falkenburg JH, Heemskerk
MH. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic
malignancies. Haematologica 2011;96:477-81.
[105] Tacken PJ, de V I, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo
loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.
[106] Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention
of graft versus host disease by inactivation of host antigen-presenting cells. Science
1999;285:412-5.
[107] Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infu-
sions mediate superior graft-versus-leukemia effects in mixed compared to fully alloge-
neic chimeras: a critical role for host antigen-presenting cells. Blood 2002;100:1903-9.
[108] Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-
host disease does not require alloantigen expression on host epithelium. Nat Med
2002;8:575-81.
[109] Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, et al.
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity
conditioning creates a platform for immunotherapy with donor lymphocyte infusion
and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Trans-
plant 2010;16:320-32.

57